Barrons
29 Jun 2026, 11:26 UTC · 2h ago
Why This Biotech Stock Is Falling After a $929 Million Buyout Lifeline
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
Barrons
29 Jun 2026, 11:26 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
What the story claims
1 claim · each scored for market impact
Zymeworks has agreed to acquire Theravance Biopharma for $17 per share. — A definitive acquisition price typically creates a strong immediate price floor and catalyst for the target company's stock.
+0.80Which stocks this story touches
The company is being acquired at a specific share price, typically representing a premium for shareholders.
The company is the acquirer; the article does not specify the financial impact or strategic benefit to Zymeworks.
Continue reading
6 related stories
[a_to_b] Zymeworks has reached a deal to acquire Theravance Biopharma for $17 a share.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
3h ago
